Rosen Law Firm Urges NMRA Investors to Act Before Crucial Litigation Deadline
NEW YORK, February 22, 2025 Rosen Law Firm, a renowned global investor rights advocacy group, has issued an advisory to stockholders of Neumora Therapeutics Inc. (NASDAQ: NMRA) concerning the purchase of common stock linked to the company s initial public offering (IPO) in September 2023. The firm emphasizes the impending deadline of April 7, 2025, for the selection of a lead plaintiff in the ongoing securities class action, which was initially lodged by the firm itself.
The class action pertains to securities allegations stemming from the registration statement and related prospectus (collaboratively referred to as the Offering Documents) associated with Neumora s IPO. Investors from the said IPO period are encouraged to seek legal counsel to discuss their rights and potential involvement in the lawsuit.
As of the publication of this article, Neumora Therapeutics share price is recorded at $1.8. The company s market performance in 2025 has been notably lackluster in comparison to the CSIMarkets index, which aggregates data from Neumora s suppliers. The year-to-date figures for Neumora have revealed a -1.72% dip, placing it behind the performance metrics of its customers.
Rosen Law Firm s reminder for investors to consider legal representation comes amid these economic setbacks. The firm, known for its commitment to defending shareholder rights in securities litigation, emphasizes the importance of participation for shareholders adversely affected by the alleged misstatements and omissions in the Offering Documents.
Investors are advised to consult with the firm or secure independent legal counsel before the critical lead plaintiff deadline to ensure their interests are duly represented in the proceedings.
Comments